| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | lpp |
| Uniprot No | P69776 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-78aa |
| 氨基酸序列 | CSSNAKIDQLSSDVQTLNAKVDQLSNDVNAMRSDVQAAKDDAARANQRLDNMATKYRK |
| 预测分子量 | 21.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LPP重组蛋白的3篇模拟参考文献，涵盖其表达、功能及应用研究：
---
1. **标题**：*Cloning, Expression, and Functional Characterization of Recombinant Human LPP Protein*
**作者**：Zhang S, Li L, et al.
**摘要**：本研究成功克隆了人源LPP基因，通过大肠杆菌表达系统获得高纯度重组蛋白，并验证其在调控细胞粘附和迁移中的生物学功能，为后续机制研究奠定基础。
2. **标题**：*LPP Recombinant Protein Suppresses Tumor Metastasis via Modulating Focal Adhesion Kinase Signaling*
**作者**：Wang W, Zhao Z.
**摘要**：研究发现，LPP重组蛋白通过抑制黏着斑激酶(FAK)信号通路，显著降低肿瘤细胞的侵袭能力，提示其在抗肿瘤治疗中的潜在应用价值。
3. **标题**：*Optimized Production of LPP Recombinant Protein in Pichia pastoris and Its Role in Wound Healing*
**作者**：Chen Q, Zhou B.
**摘要**：利用毕赤酵母系统高效表达LPP重组蛋白，优化发酵条件后产量提升3倍，并证明该蛋白可加速体外伤口愈合模型中的细胞迁移过程。
---
以上文献摘要概括了LPP重组蛋白的基因表达优化、抗肿瘤机制及在组织修复中的应用，覆盖了基础研究与潜在应用方向。
LPP (Late Pregnancy Protein) recombinant protein, also known as Placental Protein 12 (PP12), is a low-molecular-weight glycoprotein initially identified in human placental tissue during late gestation. Structurally, it belongs to the lipocalin protein family, characterized by a conserved β-barrel structure that facilitates ligand binding and transport. Naturally expressed in reproductive tissues, LPP is associated with fetal development, immunomodulation, and angiogenesis, though its precise physiological role remains under investigation.
The recombinant form of LPP is produced using biotechnological platforms such as E. coli, yeast, or mammalian cell expression systems. These systems enable scalable production of the protein with high purity and consistency, circumventing ethical and supply limitations of native extraction. Advances in protein engineering have further optimized its stability and solubility for therapeutic applications.
LPP recombinant protein has garnered interest for its potential in biomedical research and clinical applications. Studies suggest its involvement in regulating cellular proliferation and apoptosis, making it a candidate for cancer research. Its immunomodulatory properties are being explored for autoimmune disease therapies, while its angiogenic functions have implications for wound healing and cardiovascular repair. Additionally, LPP serves as a biomarker in diagnostic assays for pregnancy-related complications and certain cancers.
Recent preclinical studies highlight its role in drug delivery systems due to its ligand-binding capacity, enabling targeted transport of therapeutic molecules. Despite promising attributes, challenges persist in fully elucidating its signaling pathways and receptor interactions. Ongoing research aims to validate its therapeutic efficacy and safety profiles in clinical trials, positioning LPP recombinant protein as a versatile tool in both translational medicine and biopharmaceutical development.
×
